Ownership and insider activity for Caris Life Sciences, Inc. (CAI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Price
| Price | $31.07 |
| Market Cap | $8.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-03 | Spetzler David Baxley | M-Exempt | 1,000,000 | $2.4M |
| 2026-09-04 | Spetzler David Baxley | M-Exempt | 250,000 | $610K |
| 2026-09-04 | Spetzler David Baxley | S-Sale | 119,212 | $3.0M |
| 2026-09-03 | Spetzler David Baxley | S-Sale | 393,100 | $9.7M |
| 2026-09-03 | Spetzler David Baxley | S-Sale | 84,900 | $2.1M |
| 2026-09-03 | Spetzler David Baxley | M-Exempt | 1,000,000 | $2.4M |
| 2026-09-04 | Spetzler David Baxley | M-Exempt | 250,000 | $610K |
| 2026-08-14 | CASTLEMAN PETER M | A-Award | 13,192 | |
| 2026-08-14 | PHILLIPS T DANNY | A-Award | 13,192 | |
| 2026-08-14 | Minor Lloyd | A-Award | 13,192 |
Balance Sheet (10y)
| Year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.6M | $46.1M | $35.4M | $45.3M | $46.5M | $53.5M | $107.2M | $56.4M | $64.0M | $797.8M |
| Short-term Investments | $21.2M | $20.0M | $30.1M | $76.0M | 0 | $79.0M | $302.4M | $65.2M | $2.2M | $2.3M |
| Receivables | $76.4M | $83.7M | $100.7M | $171.9M | $159.7M | $144.3M | $40.2M | $55.3M | $88.2M | $112.1M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $47.0M | $49.0M | $39.6M | 0 |
| Total Current Assets | $144.1M | $135.2M | $140.3M | $220.0M | $499.1M | $214.7M | $516.0M | $242.6M | $215.7M | $997.8M |
| Property, Plant & Equipment | $1.75B | $1.81B | $2.01B | $2.27B | $1.82B | $1.78B | $138.0M | $147.5M | $102.8M | $63.2M |
| Goodwill | $2.9M | $15.8M | $15.8M | $15.8M | $15.8M | 0 | $19.3M | $19.3M | $19.3M | $19.3M |
| Intangible Assets | $1.2M | $9.7M | $7.7M | $5.7M | $4.1M | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.99B | $2.06B | $2.43B | $3.01B | $2.90B | $2.61B | $717.4M | $412.9M | $343.7M | $1.13B |
| Accounts Payable | $12.0M | $13.8M | $7.8M | $7.4M | $7.3M | $3.7M | $27.3M | $26.7M | $27.8M | $39.2M |
| Short-term Debt | $172.4M | $95.5M | $132.0M | $311.4M | $218.1M | $183.4M | $52.8M | $167000 | $60.0M | $169000 |
| Total Current Liabilities | $217.9M | $164.0M | $259.9M | $425.5M | $287.4M | $320.2M | $136.9M | $95.1M | $165.4M | $127.1M |
| Long-term Debt | $1.26B | $1.38B | $1.57B | $1.85B | $1.88B | $1.56B | $169.6M | $166.1M | $319.2M | $378.8M |
| Total Liabilities | $1.53B | $1.60B | $1.87B | $2.31B | $2.21B | $1.91B | $2.42B | $2.56B | $2.84B | $548.4M |
| Retained Earnings | $319.7M | $324.6M | $397.6M | $471.1M | $493.3M | $503.3M | -$1.68B | -$2.12B | -$2.47B | -$2.55B |
| Total Equity | $460.3M | $457.5M | $563.8M | $701.1M | $693.2M | $702.2M | -$1.70B | -$2.14B | -$2.50B | $577.3M |
| Total Debt | $1.43B | $1.48B | $1.70B | $2.16B | $2.10B | $1.75B | $270.9M | $217.3M | $424.3M | $379.0M |
| Net Debt | $1.36B | $1.41B | $1.64B | $2.04B | $2.05B | $1.61B | -$138.8M | $95.7M | $358.1M | -$421.1M |
| Working Capital | -$73.8M | -$28.9M | -$119.6M | -$205.5M | $211.7M | -$105.6M | $379.1M | $147.5M | $50.3M | $870.7M |
Financial Health
| Debt / Equity | 0.76 |
| Current Ratio | 5.53 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 6.95 |
Profitability
| Return on Equity | 18.77% |
| Return on Invested Capital | 14.67% |
| Return on Assets | 8.55% |
| Gross Margin | 69.66% |
| Operating Margin | 15.49% |
| Net Margin | 10.62% |
Related companies: ABVX · CORT · CYTK · HALO · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of CAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks